Health and Healthcare
Arena Withdraws Application for Weight-Loss Drug Approval in Europe
Published:
Last Updated:
Arena made its announcement last night when it reported first-quarter earnings. The company said it is “currently evaluating the best approach for submitting at a later date.”
Belviq is one of three new weight-loss drugs from different makers, and was the first new medicine of its kind to receive U.S. Food and Drug Administration (FDA) approval in 13 years. Qsymia, from Vivus Inc. (NASDAQ: VVUS) and Contrave from Orexigen Therapeutics Inc. (NASDAQ: OREX) are the others. Qsymia has also received FDA approval while Orexigen is expected to reapply for Contrave approval later this year or early next.
Arena is likely to have withdrawn its application in order to avoid being rejected by the European regulators. None of the three competing weight-loss drugs has been approved for use in Europe.
Shares of Arena are getting hammered in premarket trading this morning, down about 14.4% to $7.19, in a 52-week range of $2.32 to $13.50.
Shares of Vivus are up 2.7%, at $13.30 in a 52-week range of $9.86 to $31.21.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
